Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
about
Circulating biomarkers to monitor cancer progression and treatmentCirculating tumor DNA: a promising biomarker in the liquid biopsy of cancerCirculating Tumor DNA as Biomarkers for Cancer Detection.Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity ConsiderationsSensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forcesIDH1 mutation detection by droplet digital PCR in glioma.Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanomaQuantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer PatientsSimple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags.Clinically Meaningful Use of Blood Tumor Markers in Oncology.Current and Emerging Applications of Droplet Digital PCR in Oncology.Circulating biomarkers for gliomas.Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report.Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patientsLiquid Biopsy and its Potential for Management of Hepatocellular Carcinoma.Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials.Standard melanoma-associated markers do not identify the MM127 metastatic melanoma cell line.Metastatic pathways in patients with cutaneous melanoma.COLD-PCR Technologies in the Area of Personalized Medicine: Methodology and Applications.Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.Tumor DNA: an emerging biomarker in head and neck cancer.Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA.Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.Characterisation of the changing genomic landscape of metastatic melanoma using cell free DNA.Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma.Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.CUT-PCR: CRISPR-mediated, ultrasensitive detection of target DNA using PCR.A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma.Circulating BRAFV600E levels correlate with treatment in patients with thyroid carcinoma.Circulating tumour-derived DNA in metastatic soft tissue sarcoma.PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma.Centrifugation-free extraction of circulating nucleic acids using immiscible liquid under vacuum pressure.
P2860
Q26745985-143F6448-7119-4631-A386-2064FD5F58F0Q26746010-33777FD9-4027-49DB-94E0-D073A48F7924Q33632125-9AEEF79F-C60C-408E-BE90-51E0D5140559Q33823065-F369D9E8-0288-45A9-8A1E-17B6F4EB4016Q35978724-AC1640B4-CC1C-4828-BB0E-F5AB3A2D5FCAQ36077810-DDC075CD-0C40-4D85-A392-975198AF9147Q36414816-9224CE59-4E00-4DDD-A091-A8EA5BC4D8DBQ36507245-882837EA-42FC-42B2-9E18-68754A372AC8Q36545444-CBE688A8-991F-4D33-900C-03AE4650D05FQ36561655-8086C941-53EC-46CB-8E21-F24E3F59C26FQ36815383-CFD04DE8-D866-44E2-81F9-5C4043A903F6Q36846985-3F16B9D9-9B14-481D-A7A0-0DCECC2B79A1Q37112945-C1F9A664-873F-452D-9679-4753367B342DQ37500722-8815600C-47B3-4D32-BCE4-6DFA6141842BQ38374623-18B88EBC-D47D-46D1-AD50-A8D886B22869Q38586617-7591EE5A-0014-47E4-931A-DA4D0368B30EQ38661826-721BF716-820F-4488-A4BA-AF2DF1F5EFA8Q38700529-535C0C51-8D9A-4BB5-BDF3-C9222F6E4290Q38770935-7FBDB750-DFA7-420A-B16D-DA76D9F9A511Q38773565-13FC7766-775C-4138-B92F-718B0091B114Q38774106-517745DA-6057-47A2-839C-F4A286348851Q38777498-C8845A71-363B-4DDB-AC11-17DC9A8A6F9CQ39024316-C0775CF4-0F3C-4C82-AB23-23F53D926CC3Q39094514-3BA73EC3-C693-42D0-BE9F-38BF34602F7DQ39292740-9414881E-B864-4254-A9EF-7C56518A470DQ40085419-D0FF26F8-3A01-4644-9606-DE821D961C97Q40091164-378692EA-8987-4FB9-99B5-1CE7754E081DQ40413630-EE782CCC-CF03-4A20-81A1-DC3EF2F62BB5Q40429924-49F5E22E-89DD-49DC-BC03-8943B0AFD39DQ40464058-F02BA15D-0503-4AA8-B1D6-7AC032872CDCQ42641203-59299736-C544-4F7C-AD7A-7E1B24A34D64Q43274590-C2DC1939-322C-40A0-AF1D-19A0387027EDQ47116036-04A20F3D-F266-4F9D-896F-FE8793E962F1Q47162594-16406C0B-B1D5-420C-AF6E-0E095F6E6A3EQ48178985-E41F711F-28E7-4BE2-9D27-E6198BCCAD7DQ49464812-CF6226E7-2098-431D-9856-72FC466AE046Q49600551-2B418F8A-CF3F-4B9E-B510-7677A143D08AQ52356767-69AD72AD-0A90-4966-A718-133F8E93A33DQ52431428-6A0F13F7-DFB2-4E3C-9929-5E3E3DC8CAB6Q52721890-DC899AAB-87AE-498E-8685-B7FFD80A0203
P2860
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Monitoring response to therapy ...... R for BRAF and NRAS mutations.
@ast
Monitoring response to therapy ...... R for BRAF and NRAS mutations.
@en
type
label
Monitoring response to therapy ...... R for BRAF and NRAS mutations.
@ast
Monitoring response to therapy ...... R for BRAF and NRAS mutations.
@en
prefLabel
Monitoring response to therapy ...... R for BRAF and NRAS mutations.
@ast
Monitoring response to therapy ...... R for BRAF and NRAS mutations.
@en
P2093
P2860
P50
P356
P1433
P1476
Monitoring response to therapy ...... CR for BRAF and NRAS mutations
@en
P2093
Christopher Hudson
Jonathan Weiss
Simon Chang-Hao Tsao
P2860
P2888
P356
10.1038/SREP11198
P407
P577
2015-06-22T00:00:00Z